Concepts (323)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spinal Cord Injuries | 13 | 2024 | 69 | 3.340 |
Why?
|
| Spinal Fusion | 8 | 2026 | 157 | 2.010 |
Why?
|
| Brain Injuries, Traumatic | 8 | 2021 | 46 | 1.560 |
Why?
|
| Sorghum | 6 | 2022 | 7 | 1.420 |
Why?
|
| Neurosurgical Procedures | 6 | 2022 | 236 | 1.390 |
Why?
|
| Decompression, Surgical | 5 | 2021 | 81 | 1.340 |
Why?
|
| Time-to-Treatment | 2 | 2020 | 33 | 1.200 |
Why?
|
| Deep Brain Stimulation | 4 | 2022 | 11 | 1.150 |
Why?
|
| Frailty | 3 | 2023 | 24 | 1.140 |
Why?
|
| Cervical Vertebrae | 9 | 2024 | 123 | 0.960 |
Why?
|
| Cervical Cord | 4 | 2024 | 8 | 0.920 |
Why?
|
| Chordoma | 2 | 2026 | 15 | 0.880 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2021 | 845 | 0.870 |
Why?
|
| Spinal Neoplasms | 2 | 2026 | 46 | 0.860 |
Why?
|
| Seeds | 3 | 2021 | 15 | 0.850 |
Why?
|
| Humans | 63 | 2026 | 29202 | 0.850 |
Why?
|
| Edible Grain | 5 | 2022 | 9 | 0.830 |
Why?
|
| Autistic Disorder | 1 | 2024 | 12 | 0.820 |
Why?
|
| Spinal Injuries | 2 | 2024 | 15 | 0.810 |
Why?
|
| Autism Spectrum Disorder | 1 | 2024 | 25 | 0.800 |
Why?
|
| Recovery of Function | 4 | 2022 | 123 | 0.780 |
Why?
|
| Mental Recall | 4 | 2017 | 51 | 0.770 |
Why?
|
| Plant Breeding | 2 | 2022 | 5 | 0.730 |
Why?
|
| Epilepsy, Post-Traumatic | 1 | 2021 | 1 | 0.710 |
Why?
|
| Thoracic Vertebrae | 2 | 2020 | 70 | 0.660 |
Why?
|
| Thoracotomy | 1 | 2020 | 17 | 0.650 |
Why?
|
| Adult | 27 | 2026 | 8125 | 0.650 |
Why?
|
| Adaptation, Physiological | 1 | 2021 | 177 | 0.620 |
Why?
|
| Theta Rhythm | 4 | 2021 | 4 | 0.610 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 468 | 0.590 |
Why?
|
| Retrospective Studies | 16 | 2023 | 2659 | 0.580 |
Why?
|
| Treatment Outcome | 12 | 2026 | 2442 | 0.550 |
Why?
|
| Female | 32 | 2026 | 15819 | 0.540 |
Why?
|
| Gamma Rhythm | 2 | 2014 | 3 | 0.530 |
Why?
|
| Male | 31 | 2026 | 14120 | 0.530 |
Why?
|
| Memory, Episodic | 2 | 2014 | 21 | 0.530 |
Why?
|
| Middle Aged | 25 | 2026 | 7493 | 0.510 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2017 | 34 | 0.510 |
Why?
|
| Tarlov Cysts | 1 | 2016 | 3 | 0.470 |
Why?
|
| Paraspinal Muscles | 1 | 2016 | 11 | 0.470 |
Why?
|
| Laminectomy | 1 | 2016 | 31 | 0.470 |
Why?
|
| Electroencephalography | 6 | 2021 | 143 | 0.460 |
Why?
|
| Low Back Pain | 1 | 2016 | 29 | 0.460 |
Why?
|
| Microsurgery | 1 | 2016 | 51 | 0.460 |
Why?
|
| Prospective Studies | 11 | 2025 | 1287 | 0.460 |
Why?
|
| Oxylipins | 3 | 2019 | 8 | 0.440 |
Why?
|
| Cyclopentanes | 3 | 2019 | 17 | 0.440 |
Why?
|
| Cerebral Cortex | 2 | 2014 | 136 | 0.420 |
Why?
|
| Scoliosis | 2 | 2025 | 36 | 0.400 |
Why?
|
| Trauma Centers | 3 | 2021 | 125 | 0.390 |
Why?
|
| Spinal Cord Neoplasms | 2 | 2025 | 40 | 0.390 |
Why?
|
| Cohort Studies | 5 | 2022 | 903 | 0.380 |
Why?
|
| Brain Concussion | 3 | 2018 | 53 | 0.370 |
Why?
|
| United States | 8 | 2022 | 2269 | 0.360 |
Why?
|
| Movement | 2 | 2024 | 100 | 0.360 |
Why?
|
| Aged | 16 | 2026 | 5647 | 0.350 |
Why?
|
| Length of Stay | 8 | 2021 | 248 | 0.350 |
Why?
|
| Cost-Benefit Analysis | 2 | 2022 | 116 | 0.340 |
Why?
|
| Spinal Fractures | 2 | 2024 | 44 | 0.320 |
Why?
|
| Postoperative Complications | 6 | 2023 | 643 | 0.310 |
Why?
|
| Spinal Cord | 4 | 2021 | 214 | 0.310 |
Why?
|
| Language | 2 | 2024 | 66 | 0.300 |
Why?
|
| Common Data Elements | 2 | 2020 | 2 | 0.300 |
Why?
|
| Diskectomy | 2 | 2020 | 23 | 0.290 |
Why?
|
| Glasgow Coma Scale | 4 | 2021 | 22 | 0.290 |
Why?
|
| Ilium | 2 | 2026 | 10 | 0.280 |
Why?
|
| Brain | 3 | 2021 | 774 | 0.280 |
Why?
|
| Bone Screws | 2 | 2026 | 46 | 0.270 |
Why?
|
| Lumbar Vertebrae | 3 | 2023 | 129 | 0.260 |
Why?
|
| Memory | 2 | 2017 | 76 | 0.250 |
Why?
|
| Pelvic Bones | 1 | 2026 | 18 | 0.240 |
Why?
|
| Sports | 2 | 2016 | 25 | 0.240 |
Why?
|
| Verbal Learning | 2 | 2016 | 14 | 0.230 |
Why?
|
| Oligodendroglioma | 1 | 2025 | 13 | 0.230 |
Why?
|
| Emergency Service, Hospital | 2 | 2017 | 124 | 0.230 |
Why?
|
| Cognition Disorders | 2 | 2018 | 186 | 0.220 |
Why?
|
| Brain Mapping | 3 | 2017 | 208 | 0.220 |
Why?
|
| Neurologic Examination | 1 | 2024 | 22 | 0.220 |
Why?
|
| Athletic Injuries | 2 | 2016 | 122 | 0.220 |
Why?
|
| Pilot Projects | 7 | 2022 | 467 | 0.210 |
Why?
|
| Reoperation | 2 | 2022 | 159 | 0.210 |
Why?
|
| Criminal Law | 1 | 2024 | 6 | 0.210 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2016 | 557 | 0.200 |
Why?
|
| Gene Expression Regulation, Plant | 3 | 2019 | 75 | 0.200 |
Why?
|
| Patient Discharge | 3 | 2020 | 111 | 0.200 |
Why?
|
| Texas | 2 | 2021 | 140 | 0.190 |
Why?
|
| Plant Proteins | 3 | 2019 | 68 | 0.190 |
Why?
|
| Ossification of Posterior Longitudinal Ligament | 1 | 2022 | 2 | 0.190 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2022 | 2 | 0.190 |
Why?
|
| Incidence | 2 | 2021 | 580 | 0.180 |
Why?
|
| Lymphoma, B-Cell | 1 | 2022 | 19 | 0.180 |
Why?
|
| Young Adult | 5 | 2024 | 2875 | 0.180 |
Why?
|
| Spondylolisthesis | 1 | 2022 | 12 | 0.180 |
Why?
|
| Treatment Failure | 1 | 2022 | 76 | 0.180 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2023 | 81 | 0.180 |
Why?
|
| Parkinson Disease | 1 | 2022 | 47 | 0.180 |
Why?
|
| Central Cord Syndrome | 1 | 2021 | 2 | 0.170 |
Why?
|
| Vancomycin | 1 | 2021 | 59 | 0.170 |
Why?
|
| Cognitive Dysfunction | 1 | 2025 | 271 | 0.170 |
Why?
|
| Germination | 1 | 2021 | 8 | 0.170 |
Why?
|
| Neurosurgery | 1 | 2022 | 77 | 0.170 |
Why?
|
| Self Report | 1 | 2021 | 124 | 0.170 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2021 | 5 | 0.170 |
Why?
|
| Hospital Charges | 1 | 2020 | 8 | 0.170 |
Why?
|
| Cold Temperature | 1 | 2021 | 35 | 0.170 |
Why?
|
| Surgical Wound Infection | 1 | 2021 | 108 | 0.170 |
Why?
|
| Malpractice | 1 | 2020 | 8 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 484 | 0.160 |
Why?
|
| Virus Replication | 1 | 2021 | 66 | 0.160 |
Why?
|
| Lumbosacral Region | 2 | 2021 | 22 | 0.160 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 79 | 0.160 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 1021 | 0.160 |
Why?
|
| Alleles | 2 | 2019 | 358 | 0.160 |
Why?
|
| RNA | 1 | 2021 | 111 | 0.160 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2020 | 9 | 0.150 |
Why?
|
| Plant Development | 1 | 2019 | 10 | 0.150 |
Why?
|
| Crops, Agricultural | 1 | 2019 | 19 | 0.150 |
Why?
|
| Fatty Acid Desaturases | 1 | 2019 | 16 | 0.150 |
Why?
|
| Neuropsychological Tests | 3 | 2018 | 249 | 0.150 |
Why?
|
| Patient Safety | 1 | 2020 | 39 | 0.150 |
Why?
|
| Software | 1 | 2021 | 128 | 0.150 |
Why?
|
| Fertility | 1 | 2019 | 60 | 0.150 |
Why?
|
| Constriction, Pathologic | 1 | 2019 | 36 | 0.150 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 277 | 0.150 |
Why?
|
| Recurrent Laryngeal Nerve Injuries | 1 | 2018 | 1 | 0.140 |
Why?
|
| Axis, Cervical Vertebra | 1 | 2018 | 3 | 0.140 |
Why?
|
| Risk Factors | 2 | 2021 | 2144 | 0.140 |
Why?
|
| Postoperative Hemorrhage | 1 | 2018 | 33 | 0.140 |
Why?
|
| Immunity, Innate | 1 | 2021 | 234 | 0.140 |
Why?
|
| Antifibrinolytic Agents | 1 | 2018 | 26 | 0.140 |
Why?
|
| Inflorescence | 1 | 2018 | 2 | 0.140 |
Why?
|
| Plant Growth Regulators | 1 | 2018 | 9 | 0.140 |
Why?
|
| Photic Stimulation | 2 | 2017 | 71 | 0.140 |
Why?
|
| Epilepsy | 2 | 2017 | 37 | 0.140 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 431 | 0.140 |
Why?
|
| Multiple Sclerosis | 1 | 2019 | 92 | 0.140 |
Why?
|
| Fractures, Bone | 1 | 2018 | 46 | 0.130 |
Why?
|
| Spine | 1 | 2018 | 63 | 0.130 |
Why?
|
| Cheek | 1 | 2017 | 10 | 0.130 |
Why?
|
| Unconsciousness | 1 | 2017 | 4 | 0.130 |
Why?
|
| Apolipoprotein E4 | 1 | 2017 | 20 | 0.130 |
Why?
|
| Laminoplasty | 1 | 2017 | 2 | 0.130 |
Why?
|
| Surgical Flaps | 1 | 2017 | 24 | 0.130 |
Why?
|
| Blood Alcohol Content | 1 | 2017 | 6 | 0.130 |
Why?
|
| Skull Base | 1 | 2017 | 35 | 0.130 |
Why?
|
| Drug Approval | 1 | 2017 | 12 | 0.130 |
Why?
|
| Research Support as Topic | 1 | 2017 | 11 | 0.130 |
Why?
|
| Drug Industry | 1 | 2017 | 15 | 0.130 |
Why?
|
| Conflict of Interest | 1 | 2017 | 17 | 0.130 |
Why?
|
| Gossypium | 1 | 2017 | 5 | 0.130 |
Why?
|
| Endoscopy | 1 | 2017 | 57 | 0.130 |
Why?
|
| Droughts | 1 | 2017 | 23 | 0.130 |
Why?
|
| Memory Disorders | 1 | 2017 | 50 | 0.130 |
Why?
|
| Spondylosis | 1 | 2017 | 15 | 0.130 |
Why?
|
| Vasoconstrictor Agents | 1 | 2017 | 35 | 0.130 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2016 | 7 | 0.130 |
Why?
|
| Shock | 1 | 2017 | 18 | 0.130 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2016 | 7 | 0.130 |
Why?
|
| Oryza | 1 | 2017 | 42 | 0.130 |
Why?
|
| Fourth Ventricle | 1 | 2016 | 4 | 0.120 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 2016 | 8 | 0.120 |
Why?
|
| Ependymoma | 1 | 2016 | 12 | 0.120 |
Why?
|
| Temporal Lobe | 1 | 2016 | 33 | 0.120 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2017 | 72 | 0.120 |
Why?
|
| Nerve Net | 2 | 2014 | 112 | 0.120 |
Why?
|
| Neuronal Plasticity | 1 | 2016 | 51 | 0.120 |
Why?
|
| Odontoid Process | 1 | 2016 | 13 | 0.120 |
Why?
|
| Registries | 3 | 2024 | 399 | 0.120 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2015 | 11 | 0.120 |
Why?
|
| Adipose Tissue | 1 | 2017 | 197 | 0.120 |
Why?
|
| Blood Pressure | 1 | 2017 | 358 | 0.120 |
Why?
|
| Amino Acid Substitution | 1 | 2015 | 105 | 0.110 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2016 | 72 | 0.110 |
Why?
|
| Brain Injuries | 1 | 2015 | 50 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 1033 | 0.110 |
Why?
|
| Oxygen | 1 | 2016 | 238 | 0.110 |
Why?
|
| Mass Screening | 1 | 2016 | 160 | 0.110 |
Why?
|
| Auditory Cortex | 1 | 2014 | 2 | 0.110 |
Why?
|
| Spectrum Analysis | 1 | 2014 | 33 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 221 | 0.100 |
Why?
|
| Functional Laterality | 1 | 2014 | 64 | 0.100 |
Why?
|
| Ocular Physiological Phenomena | 1 | 2014 | 3 | 0.100 |
Why?
|
| Seizures | 1 | 2014 | 49 | 0.100 |
Why?
|
| Time Factors | 2 | 2015 | 1619 | 0.100 |
Why?
|
| Aging | 2 | 2023 | 1041 | 0.100 |
Why?
|
| Lung | 1 | 2016 | 389 | 0.100 |
Why?
|
| Hippocampus | 1 | 2014 | 198 | 0.100 |
Why?
|
| Neoplasms | 1 | 2022 | 887 | 0.100 |
Why?
|
| Cognition | 1 | 2015 | 331 | 0.090 |
Why?
|
| Databases, Factual | 3 | 2020 | 271 | 0.090 |
Why?
|
| Hospitalization | 3 | 2020 | 207 | 0.090 |
Why?
|
| Mutation | 3 | 2022 | 875 | 0.090 |
Why?
|
| Longitudinal Ligaments | 2 | 2022 | 4 | 0.080 |
Why?
|
| Electromyography | 2 | 2024 | 176 | 0.080 |
Why?
|
| Machine Learning | 2 | 2022 | 98 | 0.080 |
Why?
|
| Gene Ontology | 2 | 2021 | 14 | 0.080 |
Why?
|
| Genome, Plant | 2 | 2022 | 27 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 2070 | 0.070 |
Why?
|
| Morbidity | 2 | 2021 | 60 | 0.070 |
Why?
|
| Child | 3 | 2024 | 2354 | 0.070 |
Why?
|
| Spinal Cord Diseases | 2 | 2020 | 33 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 119 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 478 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 435 | 0.070 |
Why?
|
| Prevalence | 2 | 2021 | 526 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2021 | 741 | 0.060 |
Why?
|
| Plants, Genetically Modified | 2 | 2017 | 25 | 0.060 |
Why?
|
| Adolescent | 3 | 2020 | 3254 | 0.060 |
Why?
|
| Carbon Dioxide | 2 | 2017 | 94 | 0.060 |
Why?
|
| Genetic Association Studies | 2 | 2016 | 115 | 0.060 |
Why?
|
| Phenotype | 2 | 2019 | 689 | 0.060 |
Why?
|
| Genotype | 2 | 2017 | 462 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 610 | 0.060 |
Why?
|
| Transcription Factors | 2 | 2019 | 524 | 0.060 |
Why?
|
| Volition | 1 | 2024 | 6 | 0.050 |
Why?
|
| Epidural Space | 1 | 2024 | 11 | 0.050 |
Why?
|
| Upper Extremity | 1 | 2024 | 31 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2024 | 54 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2024 | 85 | 0.050 |
Why?
|
| Levodopa | 1 | 2022 | 11 | 0.050 |
Why?
|
| San Francisco | 1 | 2022 | 12 | 0.050 |
Why?
|
| Wakefulness | 1 | 2022 | 25 | 0.050 |
Why?
|
| Osteotomy | 1 | 2022 | 25 | 0.050 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2022 | 14 | 0.050 |
Why?
|
| Back Pain | 1 | 2022 | 21 | 0.050 |
Why?
|
| Decision Trees | 1 | 2022 | 8 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 150 | 0.050 |
Why?
|
| Medicaid | 1 | 2022 | 55 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2024 | 794 | 0.040 |
Why?
|
| Powders | 1 | 2021 | 20 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2022 | 49 | 0.040 |
Why?
|
| Medicare | 1 | 2022 | 126 | 0.040 |
Why?
|
| Sacrum | 1 | 2021 | 25 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2023 | 632 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2022 | 252 | 0.040 |
Why?
|
| Spatial Memory | 1 | 2021 | 16 | 0.040 |
Why?
|
| Middle East Respiratory Syndrome Coronavirus | 1 | 2021 | 2 | 0.040 |
Why?
|
| THP-1 Cells | 1 | 2021 | 3 | 0.040 |
Why?
|
| Mesocricetus | 1 | 2021 | 13 | 0.040 |
Why?
|
| Protein Engineering | 1 | 2021 | 14 | 0.040 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 21 | 0.040 |
Why?
|
| Genomics | 1 | 2022 | 126 | 0.040 |
Why?
|
| Viral Load | 1 | 2021 | 32 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2021 | 74 | 0.040 |
Why?
|
| Internet | 1 | 2022 | 129 | 0.040 |
Why?
|
| Cricetinae | 1 | 2021 | 131 | 0.040 |
Why?
|
| Receptors, Fc | 1 | 2021 | 31 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 82 | 0.040 |
Why?
|
| Leukocytes | 1 | 2021 | 72 | 0.040 |
Why?
|
| Spinal Cord Compression | 1 | 2020 | 22 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 211 | 0.040 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2020 | 1 | 0.040 |
Why?
|
| Patient Acuity | 1 | 2020 | 6 | 0.040 |
Why?
|
| Biomarkers | 1 | 2023 | 789 | 0.040 |
Why?
|
| Weight Loss | 1 | 2021 | 84 | 0.040 |
Why?
|
| Linoleic Acid | 1 | 2019 | 2 | 0.040 |
Why?
|
| alpha-Linolenic Acid | 1 | 2019 | 5 | 0.040 |
Why?
|
| Logistic Models | 1 | 2021 | 415 | 0.040 |
Why?
|
| Epitopes | 1 | 2021 | 185 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 51 | 0.040 |
Why?
|
| Neck Pain | 1 | 2019 | 7 | 0.040 |
Why?
|
| Radiculopathy | 1 | 2019 | 10 | 0.040 |
Why?
|
| Animals | 3 | 2021 | 10802 | 0.040 |
Why?
|
| Transcriptome | 1 | 2021 | 244 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 336 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2018 | 31 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2020 | 254 | 0.040 |
Why?
|
| Binding Sites | 1 | 2019 | 355 | 0.040 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2018 | 4 | 0.040 |
Why?
|
| Quality of Life | 1 | 2022 | 523 | 0.040 |
Why?
|
| Prognosis | 1 | 2020 | 817 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2018 | 21 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2019 | 697 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 344 | 0.030 |
Why?
|
| Inpatients | 1 | 2018 | 60 | 0.030 |
Why?
|
| Glasgow Outcome Scale | 1 | 2017 | 4 | 0.030 |
Why?
|
| Protein Binding | 1 | 2019 | 667 | 0.030 |
Why?
|
| Wechsler Scales | 1 | 2017 | 12 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 646 | 0.030 |
Why?
|
| Paralysis | 1 | 2017 | 11 | 0.030 |
Why?
|
| Quadriplegia | 1 | 2017 | 5 | 0.030 |
Why?
|
| Ossification, Heterotopic | 1 | 2017 | 7 | 0.030 |
Why?
|
| Intraoperative Neurophysiological Monitoring | 1 | 2017 | 10 | 0.030 |
Why?
|
| Apolipoproteins E | 1 | 2017 | 52 | 0.030 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2017 | 14 | 0.030 |
Why?
|
| Skull Base Neoplasms | 1 | 2017 | 22 | 0.030 |
Why?
|
| Cotton Fiber | 1 | 2017 | 3 | 0.030 |
Why?
|
| Agricultural Irrigation | 1 | 2017 | 3 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2017 | 23 | 0.030 |
Why?
|
| Thermotolerance | 1 | 2017 | 6 | 0.030 |
Why?
|
| Rain | 1 | 2017 | 20 | 0.030 |
Why?
|
| Evoked Potentials, Motor | 1 | 2017 | 22 | 0.030 |
Why?
|
| Photosynthesis | 1 | 2017 | 24 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 540 | 0.030 |
Why?
|
| Phylogeny | 1 | 2019 | 500 | 0.030 |
Why?
|
| Hypotension | 1 | 2017 | 20 | 0.030 |
Why?
|
| Reaction Time | 1 | 2017 | 95 | 0.030 |
Why?
|
| Partial Pressure | 1 | 2016 | 4 | 0.030 |
Why?
|
| Hyperventilation | 1 | 2016 | 4 | 0.030 |
Why?
|
| Intracranial Pressure | 1 | 2016 | 14 | 0.030 |
Why?
|
| Head Protective Devices | 1 | 2016 | 8 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2016 | 58 | 0.030 |
Why?
|
| Poaceae | 1 | 2016 | 26 | 0.030 |
Why?
|
| Valine | 1 | 2015 | 13 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 526 | 0.030 |
Why?
|
| Methionine | 1 | 2015 | 38 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2015 | 71 | 0.030 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2014 | 4 | 0.030 |
Why?
|
| Microelectrodes | 1 | 2014 | 19 | 0.030 |
Why?
|
| Beta Rhythm | 1 | 2014 | 1 | 0.030 |
Why?
|
| Delta Rhythm | 1 | 2014 | 1 | 0.030 |
Why?
|
| Alpha Rhythm | 1 | 2014 | 6 | 0.030 |
Why?
|
| Optical Imaging | 1 | 2014 | 35 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2016 | 932 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 1066 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 1213 | 0.020 |
Why?
|
| Epothilones | 1 | 2011 | 5 | 0.020 |
Why?
|
| Benzothiazoles | 1 | 2011 | 5 | 0.020 |
Why?
|
| Carboplatin | 1 | 2011 | 121 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 1502 | 0.020 |
Why?
|
| Mice | 1 | 2021 | 4867 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 328 | 0.020 |
Why?
|
| Rats | 1 | 2014 | 1595 | 0.020 |
Why?
|